IDEAYA Biosciences, Inc. Overview
Pro stress-test →IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer, integrating expertise in small-molecule drug discovery, structural biology and bioinformatics with translational biomarker capabilities. The company has built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications.
Strategic Profile
Pro stress-test →2025 marked a year of execution with broad pipeline advancement and commercial readiness activities for darovasertib, supported by a deep pipeline and cash runway into 2030 addressing multiple indications with high unmet need including uveal melanoma, small cell lung cancer, neuroendocrine cancer, breast cancer, and MTAP-deleted cancers. In 2026, the company plans to advance four registrational trials, including IDE849 (DLL3 TOP1 ADC) in neuroendocrine cancer and darovasertib in uveal melanoma, a poorest prognosis oncology indication where the majority of patients have no available FDA approved therapies.
Competitive Landscape
Pro stress-test →IDEAYA focuses on synthetic lethality and ADC-based approaches for molecularly defined solid tumors, competing within the broader precision oncology and ADC therapeutic spaces. The company differentiates through its dual-target bispecific ADC platform and focus on difficult-to-treat cancers like uveal melanoma, positioning it against both large pharma oncology divisions and specialized biotech ADC developers.
Industry Context
IDEAYA Biosciences, Inc. operates in Precision Medicine Oncology / Biotech.
Key facts
Headquarters: South San Francisco, United States